Clinical Trials Browser

INDUSTRY × Interventional × pamiparib × Clear all

NCT04164199 2026-05-08

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Active not recruiting

404 enrolled

Advanced Malignancies

NCT03519230 2026-03-16

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Phase 3 Active not recruiting

224 enrolled

Gynecologic

Ovarian Neoplasms

NCT03150862 2025-02-04

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Phase 1/2 Completed

116 enrolled 31 charts

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Nervous System Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Gliosarcoma

NCT03333915 2025-02-04

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Phase 1/2 Completed

128 enrolled 36 charts

Breast

Triple Negative Breast Neoplasms

NCT02361723 2024-12-27

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

Phase 1 Completed

101 enrolled

Other solid neoplasm

For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

NCT03150810 2024-12-20

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

139 enrolled 36 charts

BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03427814 2024-10-26